Literature DB >> 21633630

St. Gallen 2011: Summary of the Consensus Discussion.

Michael Gnant1, Nadia Harbeck, Christoph Thomssen.   

Abstract

SUMMARY: The 2011 St. Gallen Consensus Conference on early breast cancer provided mostly evidence-based treatment recommendations with a broad spectrum of acceptable clinical practice for global breast cancer care. This report summarizes the results of the 2011 international panel voting procedures with regard to locoregional and endocrine treatment, chemotherapy, targeted therapy as well as adjuvant bisphosphonate use.

Entities:  

Year:  2011        PMID： 21633630      PMCID： PMC3100376          DOI： 10.1159/000328054

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


  13 in total

1.  A new look at node-negative breast cancer.

Authors:  Nadia Harbeck; Christoph Thomssen
Journal:  Oncologist       Date:  2011

2.  First--select the target: better choice of adjuvant treatments for breast cancer patients.

Authors:  A Goldhirsch; A S Coates; R D Gelber; J H Glick; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2006-10-27       Impact factor: 32.976

3.  Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens.

Authors:  Christoph Thomssen; Nadia Harbeck; Juergen Dittmer; Shanti R Abraha-Spaeth; Nancy Papendick; Angelo Paradiso; Bjoern Lisboa; Fritz Jaenicke; Manfred Schmitt; Martina Vetter
Journal:  J Natl Cancer Inst       Date:  2009-06-17       Impact factor: 13.506

4.  Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

Authors:  H Eidtmann; R de Boer; N Bundred; A Llombart-Cussac; N Davidson; P Neven; G von Minckwitz; J Miller; N Schenk; R Coleman
Journal:  Ann Oncol       Date:  2010-05-05       Impact factor: 32.976

5.  Long-term results of hypofractionated radiation therapy for breast cancer.

Authors:  Timothy J Whelan; Jean-Philippe Pignol; Mark N Levine; Jim A Julian; Robert MacKenzie; Sameer Parpia; Wendy Shelley; Laval Grimard; Julie Bowen; Himu Lukka; Francisco Perera; Anthony Fyles; Ken Schneider; Sunil Gulavita; Carolyn Freeman
Journal:  N Engl J Med       Date:  2010-02-11       Impact factor: 91.245

6.  Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.

Authors:  David N Krag; Stewart J Anderson; Thomas B Julian; Ann M Brown; Seth P Harlow; Joseph P Costantino; Takamaru Ashikaga; Donald L Weaver; Eleftherios P Mamounas; Lynne M Jalovec; Thomas G Frazier; R Dirk Noyes; André Robidoux; Hugh Mc Scarth; Norman Wolmark
Journal:  Lancet Oncol       Date:  2010-10       Impact factor: 41.316

7.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

8.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.

Authors:  Armando E Giuliano; Kelly K Hunt; Karla V Ballman; Peter D Beitsch; Pat W Whitworth; Peter W Blumencranz; A Marilyn Leitch; Sukamal Saha; Linda M McCall; Monica Morrow
Journal:  JAMA       Date:  2011-02-09       Impact factor: 56.272

9.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Authors:  Michael Gnant; Brigitte Mlineritsch; Walter Schippinger; Gero Luschin-Ebengreuth; Sabine Pöstlberger; Christian Menzel; Raimund Jakesz; Michael Seifert; Michael Hubalek; Vesna Bjelic-Radisic; Hellmut Samonigg; Christoph Tausch; Holger Eidtmann; Günther Steger; Werner Kwasny; Peter Dubsky; Michael Fridrik; Florian Fitzal; Michael Stierer; Ernst Rücklinger; Richard Greil; C Marth
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

10.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

Authors:  A Goldhirsch; J N Ingle; R D Gelber; A S Coates; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2009-06-17       Impact factor: 32.976
View more
  69 in total

1.  Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy.

Authors:  András Vörös; Erika Csörgő; Bence Kővári; Péter Lázár; Gyöngyi Kelemen; Orsolya Rusz; Tibor Nyári; Gábor Cserni
Journal:  Pathol Oncol Res       Date:  2014-05-25       Impact factor: 3.201

2.  The use of digital images improves reproducibility of the ki-67 labeling index as a proliferation marker in breast cancer.

Authors:  András Vörös; Erika Csörgő; Bence Kővári; Péter Lázár; Gyöngyi Kelemen; Gábor Cserni
Journal:  Pathol Oncol Res       Date:  2013-11-08       Impact factor: 3.201

Review 3.  Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations.

Authors:  Nadia Harbeck; Rachel Wuerstlein
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546

4.  Optimal systemic therapy for early breast cancer in women: a clinical practice guideline.

Authors:  A Eisen; G G Fletcher; S Gandhi; M Mates; O C Freedman; S F Dent; M E Trudeau
Journal:  Curr Oncol       Date:  2015-03       Impact factor: 3.677

Review 5.  Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis.

Authors:  Yun Fu; Zhigang Zhuang
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

6.  Prognostic molecular assays on the rise for non-small cell lung cancer.

Authors:  William Sterlacci; Alexandar Tzankov
Journal:  J Thorac Dis       Date:  2012-04-01       Impact factor: 2.895

7.  The Z0011 Trial: Is this the end of axillary ultrasound in the pre-operative assessment of breast cancer patients?

Authors:  T P J Farrell; N C Adams; M Stenson; P A Carroll; M Griffin; E M Connolly; S A O'Keeffe
Journal:  Eur Radiol       Date:  2015-03-05       Impact factor: 5.315

8.  Maintenance treatment of trastuzumab for patients with advanced breast cancer to achieve long term survival: two case reports and literature review.

Authors:  Min Yan; Hui-Min Lv; Meng-Wei Zhang; Shu-De Cui
Journal:  Chin J Cancer Res       Date:  2014-08       Impact factor: 5.087

9.  High FUT3 expression is a marker of lower overall survival of breast cancer patients.

Authors:  Jessica Catarine Frutuoso do Nascimento; Eduardo Isidoro Carneiro Beltrão; Cíntia Renata Costa Rocha
Journal:  Glycoconj J       Date:  2020-02-15       Impact factor: 2.916

10.  Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis.

Authors:  Mohammed S Fayaz; Mustafa S El-Sherify; Amany El-Basmy; Sadeq A Zlouf; Nashwa Nazmy; Thomas George; Susan Samir; Gerges Attia; Heba Eissa
Journal:  Rep Pract Oncol Radiother       Date:  2013-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.